The use of sulfasalazine in the treatment of immunoglobulin a (iga) vasculitis in pediatric practice

Abstract

According to the last international conference on the nomenclature, diagnosis and treatment of vasculitis in Chapel Hill in 2012, Henoch—Schonlein purpura received a new name — IgA-vasculitis. It is believed that an increase in IgA synthesis is a compensatory mechanism in response to a developed inflammatory response. Basic therapy includes the use of antiplatelets, anticoagulant therapy, if medically required — glucocorticosteroids (GCS), cytostatics. Difficulties in diagnosis in the early stages and the likelihood of developing complications leaves Henoch—Schonlein purpura in the top of the current issues of pediatrics today. Henoch—Schonlein purpura is usually a self-limited disease with a benign course. Treatment of vasculitis is a complex task, especially in the presence of two or more combined syndromes. Recently, in the treatment of this disease the use of sulfasalazine has attracted the attention of doctors; however, reports of its use in children are limited.
Aim. To attract the attention of pediatricians to the use of medicines that are not included in the basic therapy of IgA-vasculitis.
Clinical case. A clinical case of IgA-vasculitis in a child of 17 years is described. Based on the evaluation of history, clinical examination, laboratory and instrumental methods of examination and differential diagnosis, a diagnosis of IgA-vasculitis was made.
Conclusions. The use of sulfasalazine is effective in the treatment of IgA-vasculitis.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of an institution. The informed consent of the patient was obtained for conducting the studies.No conflict of interest was declared by the authors.